Client concentration
Management states that loss of one or more large customers would have a significant negative effect on revenue.
- Scope
- Fee income and assets under management
- Materiality
- high
Case Group AB (publ) is a Swedish holding company centered on asset management through its operating subsidiary Case Kapitalförvaltning AB. The group develops and manages investment funds and related portfolio management services for clients in Sweden and other Nordic markets.
| % | |
|---|---|
| Mutual funds | 70% Actively managed funds across equity, credit, and multi-asset strategies. |
| Asset management fees | 25% Ongoing management and performance-related fees tied to assets under management. |
| Fund mergers and launches | 5% Internal fund restructuring, mergers, and new fund offerings that shape the product shelf. |
Case Group serves investors who allocate capital into its funds, including retail savers and professional clients using...
Buy mutual funds for long-term savings and diversified exposure to equities and credit.
Allocate to Case funds through advisers or institutional channels for specific mandates.
Remain invested in legacy and merged funds that continue to contribute to AUM and fees.
Invest in newly launched strategies such as multi-strategy or micro-cap funds.
Case Group is headquartered in Sweden and its business is centered on the Nordic fund market, especially Sweden...
Case Group’s strategy is to grow assets under management by broadening its fund range and strengthening client...
A broader product set can attract new investor segments and reduce dependence on a few mandates.
Fee income depends on managed capital, so AUM growth is central to revenue expansion.
Merging overlapping funds can improve clarity for investors and reduce operating complexity.
Case Group is exposed to concentration risk because fee income depends on a relatively limited set of funds and clients...
Management states that loss of one or more large customers would have a significant negative effect on revenue.
Fund values and management fees depend on market levels and relative investment performance.
Asset management is heavily regulated and requires ongoing compliance, risk control, and reporting.
The annual report notes that inability to meet payment obligations could have serious consequences.
CRSP · Biological Products, (No Diagnostic Substances)
CRISPR Therapeutics AG is a gene-editing biopharmaceutical company built around CRISPR/Cas9 technology and the development of gene-based medicines for serious diseases.
CRBU · Biological Products, (No Diagnostic Substances)
CSTL · Services-Medical Laboratories
Castle Biosciences is a U.S.-based molecular diagnostics company that develops tissue-based tests to help clinicians make treatment and diagnosis decisions in…
FATE · Biological Products, (No Diagnostic Substances)
Fate Therapeutics is a clinical-stage biopharmaceutical company developing off-the-shelf cellular immunotherapies built from human induced pluripotent stem cells (iPSCs).
SYBX · Pharmaceutical Preparations
IMA · Biological Products, (No Diagnostic Substances)
: 11/08/2026